Screener
Mirum Pharmaceuticals, Inc. MIRM Product sales, net — Product sales, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales, net: | ||||
| Livmarli | $128,721 | $88,160 | $242,525 | $161,384 |
| Bile Acid Medicines | 47,522 | 39,625 | 93,600 | 77,986 |
| Total product sales, net | $176,243 | $127,785 | $336,125 | $239,370 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net?
- Mirum Pharmaceuticals, Inc. (MIRM) reported product sales, net — product sales, net of $176.24M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net increased by 37.9% year-over-year, from $127.79M to $176.24M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net has grown at a 259.0% compound annual growth rate (CAGR), from $3.14M to $521.31M.
- What does product sales, net — product sales, net mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for variable considerations such as rebates, discounts, returns, and allowances. It serves as a primary indicator of commercial adoption and market penetration for the company's therapeutic portfolio. Tracking this figure allows investors to assess the underlying demand for the company's approved treatments and the effectiveness of its commercialization strategy.
Ask your AI about Mirum Pharmaceuticals, Inc.'s product sales, net — product sales, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude